Annual EBIT
-$25.28 M
+$1.21 M+4.57%
December 31, 2023
Summary
- As of February 26, 2025, CASI annual earnings before interest & taxes is -$25.28 million, with the most recent change of +$1.21 million (+4.57%) on December 31, 2023.
- During the last 3 years, CASI annual EBIT has risen by +$8.03 million (+24.11%).
- CASI annual EBIT is now -461.28% below its all-time high of -$4.50 million, reached on December 31, 2012.
Performance
CASI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$8.09 M
+$1.47 M+15.38%
September 1, 2024
Summary
- As of February 26, 2025, CASI quarterly earnings before interest & taxes is -$8.09 million, with the most recent change of +$1.47 million (+15.38%) on September 1, 2024.
- Over the past year, CASI quarterly EBIT has dropped by -$3.32 million (-69.67%).
- CASI quarterly EBIT is now -818.22% below its all-time high of $1.13 million, reached on December 31, 2010.
Performance
CASI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$31.62 M
-$2.84 M-9.86%
September 1, 2024
Summary
- As of February 26, 2025, CASI TTM earnings before interest & taxes is -$31.62 million, with the most recent change of -$2.84 million (-9.86%) on September 1, 2024.
- Over the past year, CASI TTM EBIT has dropped by -$5.04 million (-18.95%).
- CASI TTM EBIT is now -1760.18% below its all-time high of -$1.70 million, reached on March 31, 1996.
Performance
CASI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
CASI EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.6% | -69.7% | -18.9% |
| 3 y3 years | +24.1% | -69.7% | -18.9% |
| 5 y5 years | +4.6% | -69.7% | -18.9% |
CASI EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +28.2% | -69.7% | +28.5% | -19.4% | +10.2% |
| 5 y | 5-year | at high | +36.1% | -69.7% | +28.5% | -19.4% | +20.1% |
| alltime | all time | -461.3% | +62.2% | -818.2% | +66.5% | -1760.2% | +55.1% |
CASI Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.09 M(-15.4%) | -$31.62 M(+9.9%) |
| Jun 2024 | - | -$9.55 M(+3.6%) | -$28.79 M(+0.9%) |
| Mar 2024 | - | -$9.22 M(+93.5%) | -$28.53 M(+7.3%) |
| Dec 2023 | -$25.28 M(-4.6%) | -$4.76 M(-9.2%) | -$26.59 M(-1.2%) |
| Sep 2023 | - | -$5.25 M(-43.6%) | -$26.92 M(-3.9%) |
| Jun 2023 | - | -$9.30 M(+27.9%) | -$28.03 M(+5.9%) |
| Mar 2023 | - | -$7.27 M(+42.6%) | -$26.47 M(-0.1%) |
| Dec 2022 | -$26.49 M(-24.8%) | -$5.10 M(-19.7%) | -$26.49 M(-19.0%) |
| Sep 2022 | - | -$6.35 M(-18.0%) | -$32.70 M(-1.6%) |
| Jun 2022 | - | -$7.75 M(+6.3%) | -$33.23 M(+2.5%) |
| Mar 2022 | - | -$7.29 M(-35.5%) | -$32.41 M(-8.0%) |
| Dec 2021 | -$35.22 M(+5.7%) | -$11.30 M(+64.0%) | -$35.22 M(+3.8%) |
| Sep 2021 | - | -$6.89 M(-0.4%) | -$33.94 M(-2.6%) |
| Jun 2021 | - | -$6.92 M(-31.4%) | -$34.84 M(-1.2%) |
| Mar 2021 | - | -$10.10 M(+0.7%) | -$35.27 M(+5.9%) |
| Dec 2020 | -$33.31 M(-15.8%) | -$10.03 M(+28.6%) | -$33.31 M(-2.0%) |
| Sep 2020 | - | -$7.80 M(+6.1%) | -$33.99 M(-7.7%) |
| Jun 2020 | - | -$7.35 M(-9.7%) | -$36.84 M(-6.6%) |
| Mar 2020 | - | -$8.14 M(-23.9%) | -$39.45 M(-0.3%) |
| Dec 2019 | -$39.58 M(+49.3%) | -$10.70 M(+0.6%) | -$39.58 M(+4.4%) |
| Sep 2019 | - | -$10.64 M(+6.8%) | -$37.90 M(+5.4%) |
| Jun 2019 | - | -$9.96 M(+20.3%) | -$35.97 M(+13.2%) |
| Mar 2019 | - | -$8.28 M(-8.2%) | -$31.78 M(+17.3%) |
| Dec 2018 | -$26.50 M(+146.4%) | -$9.02 M(+3.6%) | -$27.09 M(+17.2%) |
| Sep 2018 | - | -$8.71 M(+50.9%) | -$23.12 M(+44.3%) |
| Jun 2018 | - | -$5.77 M(+60.8%) | -$16.01 M(+26.6%) |
| Mar 2018 | - | -$3.59 M(-28.9%) | -$12.65 M(+17.6%) |
| Dec 2017 | -$10.76 M(+14.2%) | -$5.04 M(+213.3%) | -$10.76 M(+28.4%) |
| Sep 2017 | - | -$1.61 M(-33.1%) | -$8.38 M(-0.9%) |
| Jun 2017 | - | -$2.40 M(+41.8%) | -$8.45 M(-9.4%) |
| Mar 2017 | - | -$1.70 M(-36.4%) | -$9.33 M(-0.9%) |
| Dec 2016 | -$9.42 M(+32.2%) | -$2.67 M(+58.3%) | -$9.42 M(+11.5%) |
| Sep 2016 | - | -$1.68 M(-48.7%) | -$8.45 M(+1.2%) |
| Jun 2016 | - | -$3.28 M(+83.9%) | -$8.34 M(+17.0%) |
| Mar 2016 | - | -$1.79 M(+5.4%) | -$7.13 M(+0.1%) |
| Dec 2015 | -$7.12 M(-72.8%) | -$1.69 M(+7.2%) | -$7.12 M(+1.7%) |
| Sep 2015 | - | -$1.58 M(-23.7%) | -$7.00 M(-74.0%) |
| Jun 2015 | - | -$2.07 M(+16.4%) | -$26.96 M(+1.7%) |
| Mar 2015 | - | -$1.78 M(+13.1%) | -$26.50 M(+1.3%) |
| Dec 2014 | -$26.17 M(+356.0%) | -$1.57 M(-92.7%) | -$26.17 M(+1.0%) |
| Sep 2014 | - | -$21.53 M(+1232.3%) | -$25.91 M(+345.3%) |
| Jun 2014 | - | -$1.62 M(+11.4%) | -$5.82 M(-3.9%) |
| Mar 2014 | - | -$1.45 M(+10.9%) | -$6.06 M(+5.5%) |
| Dec 2013 | -$5.74 M(+27.4%) | -$1.31 M(-9.3%) | -$5.74 M(+39.7%) |
| Sep 2013 | - | -$1.44 M(-22.1%) | -$4.11 M(+6.6%) |
| Jun 2013 | - | -$1.85 M(+63.0%) | -$3.85 M(+1.5%) |
| Mar 2013 | - | -$1.14 M(-451.3%) | -$3.79 M(-15.8%) |
| Dec 2012 | -$4.50 M(-1.2%) | $323.50 K(-127.2%) | -$4.50 M(+18.1%) |
| Sep 2012 | - | -$1.19 M(-33.8%) | -$3.81 M(-1.9%) |
| Jun 2012 | - | -$1.79 M(-2.8%) | -$3.89 M(+3.5%) |
| Mar 2012 | - | -$1.85 M(-282.1%) | -$3.75 M(-17.7%) |
| Dec 2011 | -$4.56 M(+0.5%) | $1.01 M(-180.4%) | -$4.56 M(+2.5%) |
| Sep 2011 | - | -$1.26 M(-24.1%) | -$4.45 M(-14.0%) |
| Jun 2011 | - | -$1.66 M(-37.4%) | -$5.17 M(-2.3%) |
| Mar 2011 | - | -$2.65 M(-335.5%) | -$5.29 M(+16.7%) |
| Dec 2010 | -$4.53 M | $1.13 M(-156.8%) | -$4.53 M(-35.5%) |
| Sep 2010 | - | -$1.98 M(+11.3%) | -$7.03 M(+52.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2010 | - | -$1.78 M(-6.0%) | -$4.62 M(-16.1%) |
| Mar 2010 | - | -$1.90 M(+38.5%) | -$5.50 M(-18.1%) |
| Dec 2009 | -$6.72 M(-67.0%) | -$1.37 M(-418.5%) | -$6.72 M(-8.0%) |
| Sep 2009 | - | $429.50 K(-116.1%) | -$7.31 M(-32.0%) |
| Jun 2009 | - | -$2.67 M(-14.2%) | -$10.75 M(-29.8%) |
| Mar 2009 | - | -$3.11 M(+59.3%) | -$15.30 M(-24.8%) |
| Dec 2008 | -$20.36 M(-14.2%) | -$1.95 M(-35.0%) | -$20.36 M(-8.1%) |
| Sep 2008 | - | -$3.01 M(-58.4%) | -$22.16 M(-1.3%) |
| Jun 2008 | - | -$7.22 M(-11.6%) | -$22.44 M(-5.2%) |
| Mar 2008 | - | -$8.17 M(+117.7%) | -$23.67 M(-0.3%) |
| Dec 2007 | -$23.73 M(+7.0%) | -$3.75 M(+13.9%) | -$23.73 M(-9.1%) |
| Sep 2007 | - | -$3.30 M(-61.0%) | -$26.10 M(-2.7%) |
| Jun 2007 | - | -$8.45 M(+2.7%) | -$26.82 M(+9.2%) |
| Mar 2007 | - | -$8.23 M(+34.4%) | -$24.57 M(+10.8%) |
| Dec 2006 | -$22.17 M(+28.0%) | -$6.12 M(+52.4%) | -$22.17 M(+19.7%) |
| Sep 2006 | - | -$4.02 M(-35.2%) | -$18.52 M(-3.4%) |
| Jun 2006 | - | -$6.20 M(+6.4%) | -$19.17 M(+9.3%) |
| Mar 2006 | - | -$5.83 M(+135.5%) | -$17.54 M(+1.2%) |
| Dec 2005 | -$17.33 M(+4.5%) | -$2.47 M(-47.0%) | -$17.33 M(-5.4%) |
| Sep 2005 | - | -$4.67 M(+2.1%) | -$18.32 M(+5.3%) |
| Jun 2005 | - | -$4.57 M(-18.6%) | -$17.41 M(+1.5%) |
| Mar 2005 | - | -$5.61 M(+61.8%) | -$17.14 M(+3.4%) |
| Dec 2004 | -$16.58 M(-15.8%) | -$3.47 M(-7.4%) | -$16.58 M(-13.3%) |
| Sep 2004 | - | -$3.75 M(-13.0%) | -$19.12 M(-4.5%) |
| Jun 2004 | - | -$4.31 M(-14.7%) | -$20.01 M(-4.8%) |
| Mar 2004 | - | -$5.05 M(-15.9%) | -$21.01 M(+6.6%) |
| Dec 2003 | -$19.70 M(-55.3%) | -$6.01 M(+29.5%) | -$19.70 M(-2.6%) |
| Sep 2003 | - | -$4.64 M(-12.6%) | -$20.23 M(-25.9%) |
| Jun 2003 | - | -$5.31 M(+41.7%) | -$27.28 M(-17.9%) |
| Mar 2003 | - | -$3.74 M(-42.7%) | -$33.22 M(-24.6%) |
| Dec 2002 | -$44.06 M(-34.0%) | -$6.54 M(-44.1%) | -$44.06 M(-28.6%) |
| Sep 2002 | - | -$11.70 M(+4.0%) | -$61.69 M(-7.3%) |
| Jun 2002 | - | -$11.24 M(-23.0%) | -$66.53 M(-5.6%) |
| Mar 2002 | - | -$14.59 M(-39.6%) | -$70.46 M(+5.5%) |
| Dec 2001 | -$66.81 M(+31.7%) | -$24.16 M(+46.1%) | -$66.81 M(+17.7%) |
| Sep 2001 | - | -$16.54 M(+9.0%) | -$56.77 M(+8.7%) |
| Jun 2001 | - | -$15.17 M(+38.7%) | -$52.22 M(+3.2%) |
| Mar 2001 | - | -$10.94 M(-22.6%) | -$50.61 M(-0.2%) |
| Dec 2000 | -$50.72 M(+31.8%) | -$14.12 M(+17.8%) | -$50.72 M(-2.2%) |
| Sep 2000 | - | -$11.99 M(-11.6%) | -$51.88 M(+9.7%) |
| Jun 2000 | - | -$13.56 M(+22.8%) | -$47.28 M(+12.5%) |
| Mar 2000 | - | -$11.04 M(-27.8%) | -$42.02 M(+9.0%) |
| Dec 1999 | -$38.48 M(+145.1%) | -$15.28 M(+106.5%) | -$38.53 M(+35.4%) |
| Sep 1999 | - | -$7.40 M(-10.8%) | -$28.45 M(+10.9%) |
| Jun 1999 | - | -$8.29 M(+9.7%) | -$25.65 M(+30.5%) |
| Mar 1999 | - | -$7.56 M(+45.4%) | -$19.66 M(+25.2%) |
| Dec 1998 | -$15.70 M(+72.5%) | -$5.20 M(+13.0%) | -$15.70 M(+19.8%) |
| Sep 1998 | - | -$4.60 M(+100.0%) | -$13.10 M(+19.1%) |
| Jun 1998 | - | -$2.30 M(-36.1%) | -$11.00 M(+4.8%) |
| Mar 1998 | - | -$3.60 M(+38.5%) | -$10.50 M(+18.0%) |
| Dec 1997 | -$9.10 M(+42.2%) | -$2.60 M(+4.0%) | -$8.90 M(+7.2%) |
| Sep 1997 | - | -$2.50 M(+38.9%) | -$8.30 M(+6.4%) |
| Jun 1997 | - | -$1.80 M(-10.0%) | -$7.80 M(+18.2%) |
| Mar 1997 | - | -$2.00 M(0.0%) | -$6.60 M(+4.8%) |
| Dec 1996 | -$6.40 M | -$2.00 M(0.0%) | -$6.30 M(+46.5%) |
| Sep 1996 | - | -$2.00 M(+233.3%) | -$4.30 M(+87.0%) |
| Jun 1996 | - | -$600.00 K(-64.7%) | -$2.30 M(+35.3%) |
| Mar 1996 | - | -$1.70 M | -$1.70 M |
FAQ
- What is CASI Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for CASI Pharmaceuticals?
- What is CASI Pharmaceuticals annual EBIT year-on-year change?
- What is CASI Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for CASI Pharmaceuticals?
- What is CASI Pharmaceuticals quarterly EBIT year-on-year change?
- What is CASI Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for CASI Pharmaceuticals?
- What is CASI Pharmaceuticals TTM EBIT year-on-year change?
What is CASI Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of CASI is -$25.28 M
What is the all time high annual EBIT for CASI Pharmaceuticals?
CASI Pharmaceuticals all-time high annual earnings before interest & taxes is -$4.50 M
What is CASI Pharmaceuticals annual EBIT year-on-year change?
Over the past year, CASI annual earnings before interest & taxes has changed by +$1.21 M (+4.57%)
What is CASI Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of CASI is -$8.09 M
What is the all time high quarterly EBIT for CASI Pharmaceuticals?
CASI Pharmaceuticals all-time high quarterly earnings before interest & taxes is $1.13 M
What is CASI Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, CASI quarterly earnings before interest & taxes has changed by -$3.32 M (-69.67%)
What is CASI Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of CASI is -$31.62 M
What is the all time high TTM EBIT for CASI Pharmaceuticals?
CASI Pharmaceuticals all-time high TTM earnings before interest & taxes is -$1.70 M
What is CASI Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, CASI TTM earnings before interest & taxes has changed by -$5.04 M (-18.95%)